Showing 4361-4370 of 8791 results for "".
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremar
- EULAR Seeks to Classify Risk of PsA in PsO Patientshttps://practicaldermatology.com/news/eular-seeks-to-classify-risk-of-psa-in-pso-patients/2461867/New EULAR points-to-consider characterize the transition from skin to joint involvement in psoriatic disease. Overall, five overarching principles and 10 points-to-consider were formulated by a multidisciplinary task force of 30 members from 13 European countries. The principles ac
- News You Can Use: GW, Pfizer Offering Grants to Improve Access to Teledermatology in Underserved Areashttps://practicaldermatology.com/news/news-you-can-use-gw-pfizer-offering-grants-to-improve-access-to-teledermatology-in-underserved-areas/2461865/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and Pfizer Global Medical Grants are collaborating to offer a grant opportunity focused on broad implementation of GW’s Teledermatology Help Desk Clinic model in underserved areas across the United States.</
- People Who Use Skin-Lightening Products May Be in the Dark About Riskshttps://practicaldermatology.com/news/people-who-use-skin-lightening-products-may-be-in-the-dark-about-risks/2461862/Skin-lightening products can be dangerous, but users aren’t always aware of the risks, a new study finds. To conduct the study, researchers sent an anonymous 19-question survey to individuals with skin of color in the U.S. asking about their demographics, colorism attitudes, skin
- Cetuximab Plus Radiation May Be Effective Treatment for Advanced Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/cetuximab-plus-radiation-may-be-effective-treatment-for-advanced-squamous-cell-skin-cancer/2461860/Cetuximab plus radiotherapy may be an effective treatment option for locally advanced cutaneous squamous cell cancers (laCSCC), with manageable toxicity, according to a study in Oncotarget. Cetuximab is
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimi
- DFD-29 Bests Competition for Papulopustular Rosacea in Adultshttps://practicaldermatology.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults/2461858/Minocycline Hydrochloride Modified Release Capsules (DFD-29) outperformed Oracea (doxycycline) capsules and placebo for the treatment of moderate-to-severe papulopustular rosacea in adults, according to positive topline results from two Phase 3 studies. Journey Medical&rs
- MRA's RARE Registry for Acral & Mucosal Melanoma Surpasses 100-Patient Milestonehttps://practicaldermatology.com/news/mras-rare-registry-for-acral-mucosal-melanoma-surpasses-100-patient-milestone/2461850/The Melanoma Research Alliance’s (MRA) RARE Registry for acral and mucosal melanoma has officially surpassed 100 patie
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminar
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tild